Recent Research
Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
-
Updated evidence-based guidelines for optimal selection of unrelated donors and cord blood units for HCT
September 2019Dehn J, et al., Blood – A panel of immunogeneticists and other experts in the field of hematopoietic cell transplantation (HCT) has published updated evidence-based guidelines for the optimal selection of unrelated donors and cord blood units used for transplants.
The updated guidelines make recommendations for both HLA and non-HLA factors to consider in graft selection, including donor availability, donor age, patient sensitivity to HLA antigens, natural killer (NK) cell alloreactivity, and minimum total nucleated cell doses and CD34+ cell doses for cord blood units.
-
Expert Panel Issues Practical “How To” Guide on Optimal Cord Blood Transplantation
August 2017Barker JN, et al. Biol Blood Marrow Transplant – Two leading transplant organizations have joined together to publish a report on optimal practices in cord blood transplantation (CBT), including a state-of-the-art clinical “how to” guide on CBT. -
Is Cord Blood the Best Alternative Graft Source for Patients with Minimal Residual Disease?
October 2016Milano F, et al. N Engl J Med – A retrospective study of 582 patients with acute leukemia or myelodysplastic syndromes has shown that umbilical cord blood may be a superior graft choice for the approximately 70% of patients who lack an HLA-matched related donor, especially if they are minimal residual disease positive (MRD+). -
One-Year OS of 86% Achieved with Unrelated Donor HCT for Children with SCD
October 2016Shenoy S, et al Blood – This multi-center phase II trial conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) analyzed outcomes of 29 children (age range 6-19 years) with sickle cell disease (SCD) who underwent reduced-intensity conditioning unrelated donor hematopoietic cell transplantation (HCT) between 2008 and 2014. -
95% One-Year HCT Survival for Adults with Sickle Cell Disease
December 2015Krishnamurti L, et al. ASH abstract oral presentation, December 2015 – One-year overall and event-free survival probabilities were both 95% after hematopoietic cell transplantation (HCT) in adults with sickle cell disease (SCD), according to results of a multi-center study reported at the ASH Annual Meeting. -
Parallel Phase 2 Trials Confirm Utility of Both Haploidentical and Cord Blood HCT
July 2011Brunstein CG, et al. Blood – Two concurrent multi-center phase 2 studies have confirmed the utility of using unrelated double umbilical cord blood (dUCB) or HLA-haploidentical donor bone marrow grafts in reduced-intensity hematopoietic cell transplantation (HCT).